hase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Renal Cell Carcinoma with Bone Metastases: RADICA
Re: Rana R. McKay, Karla V. Ballman, Pamela J. Atherton, et al. Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Renal Cell Carcinoma with Bone Metastases: RADICAL (Alliance A031801). J Clin Oncol. 2026;44:2341–52 / Roviello, G., Antonuzzo, L.. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - ELETTRONICO. - (2026), pp. 1-2. [10.1016/j.eururo.2026.08.016]
Re: Rana R. McKay, Karla V. Ballman, Pamela J. Atherton, et al. Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Renal Cell Carcinoma with Bone Metastases: RADICAL (Alliance A031801). J Clin Oncol. 2026;44:2341–52
Roviello, Giandomenico;Antonuzzo, Lorenzo
2026
Abstract
hase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Renal Cell Carcinoma with Bone Metastases: RADICAFile in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S030228382602364X-main.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
275.68 kB
Formato
Adobe PDF
|
275.68 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



